HONG KONG – Samsung Bioepis Co. Ltd.'s recent FDA approval to market biosimilar Eticovo (etanercept-ykro) in the U.S., marking another significant step forward for the growing South Korean drugmaker, may not bring any real benefits for almost a decade. But the U.S. nod sets the stage for Bioepis to potentially nab a significant share of the etanercept biosimilar market in the future.